Login
$TRVI
$13.29 -$0.36 (2.64%) Live

Company Executives

Officer Age In this role Joined 2025 pay Source
Jennifer Good Also a director
President & CEO
Title from the Form 4 dated Feb 19, 2026
Not stated Not stated Not stated $3,944,892
David Hastings
Chief Financial Officer
64 Since 2026
this year
Not stated Not reported
James Cassella
Chief Development Officer
71 Since 2024
2 years
Not stated $1,637,220
Thomas Sciascia
Chief Scientific Officer
72 Since 2022
4 years
2011 Not reported
Farrell Simon
Chief Commercial Officer
44 Since 2023
3 years
Not stated $1,355,897

Each officer opens the passage of the filing that names them. A title that changed since the list comes from the officer's latest Form 3, 4 or 5, and its start year is not stated there. "Not stated" means the filing does not say. Pay is the proxy's Summary Compensation Table, which reports only the named executive officers.

Directors
6
serving now
Independent
0 of 1
stated in the proxy; 5 not stated
Average tenure
9.3 years
from year joined
CEO also chairs the board
No
David Meeker
Director On board Independent Committees Other public boards 2025 pay Source
David Meeker
2017
9 years
Not stated
nominating and corporate governance
Rhythm Pharmaceuticals, Inc., Pharvaris B.V. $293,430
Jennifer Good
2011
15 years
Not independent None stated Rhythm Pharmaceuticals, Inc. Paid as CEO
Michael Heffernan
2017
9 years
Not stated
audit compensation
Avalo Therapeutics, Inc., enGene Holdings Inc., Biohaven LTD $283,430
Dominick Colangelo
2020
6 years
Not stated
audit compensation
Vericel Corporation $275,930
Edward Mathers
2017
9 years
Not stated
compensation
Synlogic, Inc. $265,930
Anne VanLent
2018
8 years
Not stated
audit · Chair nominating and corporate governance
None stated $283,430

Each director opens the passage of the proxy that names them. "Not stated" means the proxy does not say; it never means "no". Pay is the proxy's Director Compensation table; the CEO is paid as an executive.

No related-party transactions disclosed

The proxy filed Apr 21, 2026 describes a review policy but reports no transactions.

Read the policy in the proxy

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support